Merck Drug Patent Portfolio

Merck owns 34 orange book drugs protected by 156 US patents with Lipfendra having the least patent protection, holding only 1 patent. And Janumet Xr with maximum patent protection, holding 12 patents. Given below is the list of Merck's drug patents along with their expiration dates.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US12251384	Particulate composition	25 Jun, 2044	Active
US12409180	Formulation Production Process	20 Feb, 2043	Active
US12358870	Solid Dispersions And Pharmaceutical Compositions Comprising A Substituted Indane And Methods For The Preparation And Use Thereof	30 Jun, 2042	Active
US11427616	Pcsk9 Antagonist Compounds	04 Feb, 2040	Active
US10603282	Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine	29 Nov, 2036	Active
US10842751	Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine	29 Nov, 2036	Active
US10335388	Combination Therapy Of A Hif-2-Alpha Inhibitor And An Immunotherapeutic Agent And Uses Thereof	14 Apr, 2036	Active
US10945950	Liquid inhalation formulation comprising RPL554	15 Sep, 2035	Active
US9956171	Liquid inhalation formulation comprising RPL554	15 Sep, 2035	Active
US9908845	Aryl ethers and uses thereof	05 Sep, 2034	Active
US9969689	Aryl ethers and uses thereof	05 Sep, 2034	Active
USRE49948	Aryl ethers and uses thereof	05 Sep, 2034	Active
US10098892	Solid dosage formulations of an orexin receptor antagonist	29 May, 2033	Active
US11980623	Solid dosage formulations of an orexin receptor antagonist	29 May, 2033	Active
US12599610	Solid Dosage Formulations Of An Orexin Receptor Antagonist	29 May, 2033	Active
US8487093	β-lactamase inhibitors	21 Mar, 2033	Active
US10603384	Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative	28 Feb, 2033	Active
US9493582	Alkylated cyclodextrin compositions and processes for preparing and using the same	27 Feb, 2033	Active
US9604948	Process for preparing substituted 5-fluoro-1H-pyrazolopyridines	26 Nov, 2032	Active
US8486975	Non-nucleoside reverse transcriptase inhibitors	30 Aug, 2032	Active
US10772888	Solid pharmaceutical compositions containing an integrase inhibitor	30 Mar, 2032	Active
US8080580	Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives	19 Dec, 2031	Active
US9062047	Crystalline form of pyrimido[6,1-A] isoquinolin-4-one compound	21 Aug, 2031	Active
US9023790	Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin	04 Jul, 2031	Active
US9358297	Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin	24 Jun, 2031	Active
US10736896	Substituted 5-fluoro-1H-pyrazolopyridines and their use	19 May, 2031	Active
US11439642	Substituted 5-fluoro-1H-pyrazolopyridines and their use	19 May, 2031	Active
US8420656	Substituted 5-fluoro-1H-pyrazolopyridines and their use	19 May, 2031	Active
US8921377	Substituted 5-fluoro-1H-pyrazolopyridines and their use	19 May, 2031	Active
US9993476	Substituted 5-flouro-1H-pyrazolopyridines and their use	19 May, 2031	Active
US8871759	Inhibitors of hepatitis C virus replication	04 May, 2031	Active
US9649311	Solid pharmaceutical compositions containing an integrase inhibitor	21 Apr, 2031	Active
US9649311	Solid pharmaceutical compositions containing an integrase inhibitor	21 Oct, 2030	Active
US9308204	Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives	21 Oct, 2030	Active
US9439902	Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives	21 Oct, 2030	Active
US9439901	Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives	21 Oct, 2030	Active
US8771733	Pharmaceutical composition containing an anti-nucleating agent	02 Jun, 2030	Active
US7951797	Substituted diazepan orexin receptor antagonists	20 Nov, 2029	Active
US7754731	Potassium salt of an HIV integrase inhibitor	11 Sep, 2029	Active
US7973040	Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors	24 Jul, 2029	Active
US10117951	Sulfoalkyl ether cyclodextrin compositions	13 Mar, 2029	Active
US8410077	Sulfoalkyl ether cyclodextrin compositions	13 Mar, 2029	Active
US9750822	Sulfoalkyl ether cyclodextrin compositions	13 Mar, 2029	Active
US7754731	Potassium salt of an HIV integrase inhibitor	11 Mar, 2029	Active
US8414921	Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin	21 Jan, 2029	Active
USRE46791	Substituted dihydroquinazolines	18 Jan, 2029	Active
US8414921	Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin	21 Jul, 2028	Active
US8450372	Formulations of suberoylanilide hydroxamic acid and methods for producing same	18 Mar, 2028	Active
US8852632	Pharmaceutical formulation containing a release rate controlling composition	28 Jan, 2028	Active
US7772178	Pharmaceutical formulations and methods of treatment using the same	11 Nov, 2027	Active
US8258132	Pharmaceutical composition of a tachykinin receptor antagonist	26 Sep, 2027	Active
US7339053	4'-C-Substituted-2-Haloadenosine Derivative	31 May, 2027	Active
US7326708	Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor	24 May, 2027	Active
US8119602	Administration of HCV protease inhibitors in combination with food to improve bioavailability	17 Mar, 2027	Active
US7456219	Polymorphs of suberoylanilide hydroxamic acid	11 Mar, 2027	Active
US7326708	Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor	24 Nov, 2026	Active
USRE44733	6-mercapto-cyclodextrin derivatives:reversal agents for drug-induced neuromuscular block	27 Jul, 2026	Expired
US8093295	Formulations of suberoylanilide hydroxamic acid and methods for producing the same	16 May, 2026	Expired
USRE44733	6-mercapto-cyclodextrin derivatives:reversal agents for drug-induced neuromuscular block	27 Jan, 2026	Expired
US7399787	Methods of treating cancer with HDAC inhibitors	09 Feb, 2025	Expired
USRE43298	Peptides as NS3-serine protease inhibitors of hepatitis C virus	22 Dec, 2024	Expired
US7196086	Substituted dihydroquinazolines	22 May, 2024	Expired
US8513255	Substituted dihydroquinazolines	22 May, 2024	Expired
US7169780	N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase	03 Apr, 2024	Expired
US7851509	Polymorphs of suberoylanilide hydroxamic acid	21 Feb, 2024	Expired
US7169780	N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase	03 Oct, 2023	Expired
US6987108	Pharmaceutical formulations of antineoplastic agents and processes of making and using the same	08 Sep, 2023	Expired
US7820660	N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase	25 Apr, 2023	Expired
US7217713	N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase	21 Apr, 2023	Expired
US7435734	N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase	21 Apr, 2023	Expired
US7652069	Polymorphs of suberoylanilide hydroxamic acid	04 Mar, 2023	Expired
US7732490	Methods of treating cancer	04 Mar, 2023	Expired
US8067472	Methods of treating Hodgkin's and non-Hodgkin's lymphoma	04 Mar, 2023	Expired
US8101663	Polymorphs of suberoylanilide hydroxamic acid	04 Mar, 2023	Expired
US7786118	Pharmaceutical formulations of antineoplastic agents	21 Feb, 2023	Expired
US8623868	Processes of making and using pharmaceutical formulations of antineoplastic agents	21 Feb, 2023	Expired
US6699871	Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes	26 Jan, 2023	Expired
US7125873	Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes	26 Jan, 2023	Expired
US7217713	N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase	21 Oct, 2022	Expired
US7435734	N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase	21 Oct, 2022	Expired
US6699871	Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes	26 Jul, 2022	Expired
US7125873	Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes	26 Jul, 2022	Expired
US8168637	Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment of diabetes	26 Jun, 2022	Expired
US6689761	Combination therapy for HIV infection	10 Feb, 2021	Expired
US6949527	6-Mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block	27 Jan, 2021	Expired
US7265009	HDP-CVD methodology for forming PMD layer	07 Aug, 2020	Expired
US7265099	Use of chemical chelators as reversal agents for drug-induced neuromuscular block	07 Aug, 2020	Expired
US5691336	Morpholine compounds are prodrugs useful as tachykinin receptor antagonists	04 Sep, 2019	Expired
US5661151	Tetrahydrofuran antifungals	19 Jul, 2019	Expired
US5691336	Morpholine compounds are prodrugs useful as tachykinin receptor antagonists	04 Mar, 2019	Expired
US6890898	Method of regulating glucose metabolism, and reagents related thereto	02 Feb, 2019	Expired
US7078381	Method of regulating glucose metabolism, and reagents related thereto	02 Feb, 2019	Expired
US7459428	Method of regulating glucose metabolism, and reagents related thereto	02 Feb, 2019	Expired
US5994329	Method for inhibiting bone resorption	17 Jan, 2019	Expired
US6015801	Method for inhibiting bone resorption	17 Jan, 2019	Expired
US6225294	Method for inhibiting bone resorption	17 Jan, 2019	Expired
US5994329	Method for inhibiting bone resorption	17 Jul, 2018	Expired
US6015801	Method for inhibiting bone resorption	17 Jul, 2018	Expired
US6225294	Method for inhibiting bone resorption	17 Jul, 2018	Expired
US6096742	Polymorphic form of a tachykinin receptor antagonist	01 Jul, 2018	Expired
US6172046	Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection	21 Mar, 2018	Expired
US6472373	Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection	21 Mar, 2018	Expired
US6645961	Dry granulation formulation for an HIV protease inhibitor	04 Mar, 2018	Expired
US5952323	Carbapenem antibiotic	15 Nov, 2017	Expired
US6063811	Compositions for a once day treatment of cyclooxygenase-2 mediated diseases	06 Nov, 2017	Expired
US5952300	Antifungal compositions	28 Sep, 2017	Expired
US6136783	Antifungal compositions	28 Sep, 2017	Expired
US6172046	Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection	21 Sep, 2017	Expired
US6472373	Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection	21 Sep, 2017	Expired
US5952323	Carbapenem antibiotic	15 May, 2017	Expired
US6063811	Compositions for a once day treatment of cyclooxygenase-2 mediated diseases	06 May, 2017	Expired
US6177074	Polyethylene glycol modified interferon therapy	01 May, 2017	Expired
US6461605	Continuous low-dose cytokine infusion therapy	01 May, 2017	Expired
US6524570	Polyethylene glycol modified interferon therapy	01 May, 2017	Expired
US6303661	Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals	24 Apr, 2017	Expired
US5952300	Antifungal compositions	28 Mar, 2017	Expired
US6136783	Antifungal compositions	28 Mar, 2017	Expired
US6177074	Polyethylene glycol modified interferon therapy	01 Nov, 2016	Expired
US6461605	Continuous low-dose cytokine infusion therapy	01 Nov, 2016	Expired
US6524570	Polyethylene glycol modified interferon therapy	01 Nov, 2016	Expired
US6340475	Extending the duration of drug release within the stomach during the fed mode	19 Sep, 2016	Expired
US6635280	Extending the duration of drug release within the stomach during the fed mode	19 Sep, 2016	Expired
US5478820	Antibiotic compounds	21 May, 2016	Expired
US5478820	Antibiotic compounds	21 Nov, 2015	Expired
US5691374	Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors	18 Nov, 2015	Expired
US5807825	Platelet aggregation inhibitors	15 Sep, 2015	Expired
US5514650	Aza cyclohexapeptide compounds	26 Jul, 2015	Expired
US5968902	Platelet aggregation inhibitors	02 Jun, 2015	Expired
US5691374	Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors	18 May, 2015	Expired
US5747447	Stable polypeptide composition	05 May, 2015	Expired
US5719147	Morpholine and thiomorpholine tachykinin receptor antagonists	17 Apr, 2015	Expired
US5716942	Treatment of migraine with morpholine tachykinin receptor antagonists	10 Feb, 2015	Expired
US5514650	Aza cyclohexapeptide compounds	26 Jan, 2015	Expired
US5462932	Oral liquid alendronate formulations	17 Nov, 2014	Expired
US5686570	Platelet aggregation inhibitors	11 Nov, 2014	Expired
US5756451	Platelet aggregation inhibitors	11 Nov, 2014	Expired
US5703079	Tetrahydrofuran antifungals	26 Aug, 2014	Expired
US5462932	Oral liquid alendronate formulations	17 May, 2014	Expired
US5512570	Treatment of emesis with morpholine tachykinin receptor antagonists	04 Mar, 2014	Expired
US5260291	Tetrazine derivatives	11 Feb, 2014	Expired
US5474995	Phenyl heterocycles as cox-2 inhibitors	24 Dec, 2013	Expired
US6239173	3-phenyl-4-(4(methylsulfonyl)phenyl)-2-(5H)-furanone as a cox-2 inhibitor	24 Dec, 2013	Expired
USRE38506	Potent inducers of terminal differentiation and methods of use thereof	29 Nov, 2013	Expired
US5378804	Aza cyclohexapeptide compounds	16 Sep, 2013	Expired
US5792746	Aza cyclohexapeptide compounds	16 Sep, 2013	Expired
US5260291	Tetrazine derivatives	11 Aug, 2013	Expired
US5652233	Antibiotic compounds	02 Aug, 2013	Expired
US7342005	Antibiotic compounds	02 Aug, 2013	Expired
US5538982	Medical use for tachykinin antagonists	23 Jul, 2013	Expired
US5474995	Phenyl heterocycles as cox-2 inhibitors	24 Jun, 2013	Expired
US6239173	3-phenyl-4-(4(methylsulfonyl)phenyl)-2-(5H)-furanone as a cox-2 inhibitor	24 Jun, 2013	Expired
US5378804	Aza cyclohexapeptide compounds	16 Mar, 2013	Expired
US5792746	Aza cyclohexapeptide compounds	16 Mar, 2013	Expired
US5652233	Antibiotic compounds	02 Feb, 2013	Expired
US7342005	Antibiotic compounds	02 Feb, 2013	Expired
US7214692	Medical use for tachykinin antagonists	18 Sep, 2012	Expired

Latest Legal Activities on Merck's Drug Patents

Given below is the list of recent legal activities going on the following drug patents of Merck.

Activity	Date	Patent Number

Payment of Maintenance Fee, 4th Year, Large Entity	25 Feb, 2026	US11439642
Expire Patent	09 Feb, 2026	US8623868
Withdrawal of Application for PTE	16 Jan, 2026	US9308204
Withdrawal of Application for PTE	16 Jan, 2026	US9308204
Withdrawal of Application for PTE	16 Jan, 2026	US9439901
Withdrawal of Application for PTE	16 Jan, 2026	US9439902
Payment of Maintenance Fee, 12th Year, Large Entity	11 Dec, 2025	US8771733
Payment of Maintenance Fee, 12th Year, Large Entity	11 Dec, 2025	US8771733
Payment of Maintenance Fee, 8th Year, Large Entity	26 Nov, 2025	US9993476
Payment of Maintenance Fee, 8th Year, Large Entity	15 Oct, 2025	US9956171
Payment of Maintenance Fee, 8th Year, Large Entity	09 Oct, 2025	USRE49948
Recordation of Patent Grant Mailed	16 Sep, 2025	US12409180
Mail Patent eGrant Notification	09 Sep, 2025	US12409180
Recordation of Patent eGrant	09 Sep, 2025	US12409180
Patent Issue Date Used in PTA Calculation	09 Sep, 2025	US12409180

Merck's Drug Patent Litigations

Merck's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Mar 22, 2001, against patent number US6689761. The petitioner , challenged the validity of this patent, with CHODAKEWITZ et al as the respondent. Click below to track the latest information on how companies are challenging Merck's patents.

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US7326708	June, 2020	Final Written Decision (10 May, 2021)	Merck Sharp & Dohme Corp. et al.	Dr. Reddy's Laboratories, Inc. et al.
US7326708	June, 2020	Final Written Decision (10 May, 2021)	Merck Sharp & Dohme Corp. et al.	Sun Pharmaceutical Industries Ltd. et al.
US7326708	October, 2019	Final Written Decision (07 May, 2021)	Merck Sharp & Dohme Corp. et al.	Mylan Pharmaceuticals, Inc.
US7326708	June, 2020	Terminated-Settled (08 Dec, 2020)	Merck Sharp & Dohme Corp.	Teva Pharmaceuticals USA, Inc.
US6340475	April, 2014	Final Written Decision (21 Sep, 2015)	Depomed, Inc.	Endo Pharmaceutical Inc. et al.
US6635280	April, 2014	Final Written Decision (21 Sep, 2015)	Depomed, Inc.	Endo Pharmaceutical Inc. et al.
US6340475	January, 2014	Final Written Decision (08 Jul, 2015)	Depomed, Inc.	Purdue Pharma L.P.
US6635280	January, 2014	Final Written Decision (08 Jul, 2015)	DepoMed, Inc.	Purdue Pharma L.P.
US5691336	December, 2014	Institution Denied (25 Jun, 2015)	Merck Sharp & Dohme Corp.	Apotex Inc. et al.
US6340475	April, 2014	Institution Denied (29 Sep, 2014)	Depomed, Inc.	Endo Pharmaceutical Inc. et al.
US6635280	April, 2014	Institution Denied (29 Sep, 2014)	Depomed, Inc.	Endo Pharmaceutical Inc. et al.
US7214692	July, 2005	Decision (18 Jan, 2006)	Russell Michael Hagan et al
US6645961	June, 2001	Decision (27 Mar, 2002)	LUI et al
US6689761	March, 2001	Decision (25 May, 2001)	CHODAKEWITZ et al

Merck Drug Patents' Oppositions Filed in EPO

Merck drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jun 11, 2008, by Teva Pharmaceutical Industries Ltd.. This opposition was filed on patent number EP04755691A. Click below to reveal the latest opposition data.

Application	Filing Date	Opposition Party	Legal Status

EP18171672A	May, 2022	Ethypharm	Granted and Under Opposition
EP18171672A	May, 2022	Generics (U.K.) Limited	Granted and Under Opposition
EP18171672A	May, 2022	Fresenius Kabi Deutschland GmbH	Granted and Under Opposition
EP18171672A	May, 2022	Aera A/S	Granted and Under Opposition
EP16198994A	Jan, 2020	Ter Meer Steinmeister & Partner Patentanwälte mbB	Granted and Under Opposition
EP16198994A	Dec, 2019	Lederer & Keller Patentanwälte Partnerschaft mbB	Granted and Under Opposition
EP05852790A	Aug, 2017	Georg Kalhammer/Stephan Teipel	Patent maintained as amended
EP05852790A	Aug, 2017	Ter Meer Steinmeister & Partner Patentanwälte mbB	Patent maintained as amended
EP05852839A	Aug, 2014	Sölch, Günter	Patent maintained as amended
EP03711372A	May, 2013	Generics [UK] Limited	Revoked
EP05077584A	Mar, 2011	APOTEX INC.	Revoked
EP02796109A	Apr, 2009	Teva Pharmaceutical Industries Ltd.	Patent maintained as amended
EP02796109A	Apr, 2009	Hexal AG	Patent maintained as amended
EP03709188A	Mar, 2009	CHEMAGIS LTD.	Opposition rejected
EP04755691A	Jun, 2008	Teva Pharmaceutical Industries Ltd.	Patent maintained as amended

Merck's Family Patents

Merck drugs have patent protection in a total of 64 countries. It's US patent count contributes only to 14.7% of its total global patent coverage. 9 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Clinical Trials

Recent Clinical Trials by Merck:

Title	Lead Sponsor	Collaborators	Status	Phases

A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)	Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	NA	ACTIVE NOT RECRUITING (Sep 1, 2026)	PHASE1
Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)	Merck Sharp & Dohme LLC	NA	ACTIVE NOT RECRUITING (Sep 1, 2026)	PHASE2
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)	Merck Sharp & Dohme LLC	NA	RECRUITING (Sep 1, 2026)	PHASE3
A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)	Merck Sharp & Dohme LLC	NA	COMPLETED (Sep 1, 2026)	PHASE2
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)	Merck Sharp & Dohme LLC	NA	ACTIVE NOT RECRUITING (Sep 1, 2026)	PHASE3
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)	Merck Sharp & Dohme LLC	NA	ACTIVE NOT RECRUITING (Sep 1, 2026)	PHASE3
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)	Merck Sharp & Dohme LLC	NA	RECRUITING (Sep 1, 2026)	PHASE2
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)	Merck Sharp & Dohme LLC	NA	RECRUITING (Sep 1, 2026)	PHASE1
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)	Merck Sharp & Dohme LLC	NA	RECRUITING (Sep 1, 2026)	PHASE2, PHASE3
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)	Merck Sharp & Dohme LLC	NA	RECRUITING (Sep 1, 2026)	PHASE1, PHASE2
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).	Merck Sharp & Dohme LLC	NA	RECRUITING (Sep 1, 2026)	PHASE3
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)	Merck Sharp & Dohme LLC	NA	RECRUITING (Sep 1, 2026)	PHASE3
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)	Merck Sharp & Dohme LLC	NA	RECRUITING (Sep 1, 2026)	PHASE3
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)	Merck Sharp & Dohme LLC	NA	RECRUITING (Sep 1, 2026)	PHASE3
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)	Merck Sharp & Dohme LLC	NA	RECRUITING (Sep 1, 2026)	PHASE3
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)	Merck Sharp & Dohme LLC	NA	ACTIVE NOT RECRUITING (Sep 1, 2026)	PHASE3
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)	Merck Sharp & Dohme LLC	NA	RECRUITING (Sep 1, 2026)	PHASE3
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)	Merck Sharp & Dohme LLC	NA	RECRUITING (Sep 1, 2026)	PHASE3
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)	Merck Sharp & Dohme LLC	NA	RECRUITING (Sep 1, 2026)	PHASE1, PHASE2
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)	Merck Sharp & Dohme LLC	NA	RECRUITING (Sep 1, 2026)	PHASE3
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]	Merck Sharp & Dohme LLC	NA	RECRUITING (Sep 1, 2026)	PHASE3
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)	Merck Sharp & Dohme LLC	NA	RECRUITING (Sep 1, 2026)	PHASE1, PHASE2
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)	Merck Sharp & Dohme LLC	NA	RECRUITING (Sep 1, 2026)	PHASE1, PHASE2
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)	Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany	NA	RECRUITING (Sep 1, 2026)	PHASE3
A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)	Merck Sharp & Dohme LLC	NA	COMPLETED (Sep 1, 2026)	PHASE2
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)	Merck Sharp & Dohme LLC	NA	RECRUITING (Sep 1, 2026)	PHASE1, PHASE2
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)	Merck Sharp & Dohme LLC	NA	RECRUITING (Sep 1, 2026)	PHASE3
A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098)	Merck Sharp & Dohme LLC	NA	RECRUITING (Sep 1, 2026)	PHASE3
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)	Merck Sharp & Dohme LLC	NA	RECRUITING (Sep 1, 2026)	PHASE3
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)	Merck Sharp & Dohme LLC	NA	RECRUITING (Sep 1, 2026)	PHASE2
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)	Merck Sharp & Dohme LLC	NA	RECRUITING (Sep 1, 2026)	PHASE1, PHASE2
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)	Merck Sharp & Dohme LLC	NA	RECRUITING (Sep 1, 2026)	PHASE2
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)	Merck Sharp & Dohme LLC	NA	RECRUITING (Sep 1, 2026)	PHASE3
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)	Merck Sharp & Dohme LLC	NA	RECRUITING (Sep 1, 2026)	PHASE1, PHASE2
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)	Merck Sharp & Dohme LLC	NA	RECRUITING (Sep 1, 2026)	PHASE1, PHASE2
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)	Merck Sharp & Dohme LLC	NA	RECRUITING (Sep 1, 2026)	PHASE2
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)	Merck Sharp & Dohme LLC	NA	RECRUITING (Sep 1, 2026)	PHASE3
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)	Merck Sharp & Dohme LLC	NA	RECRUITING (Sep 1, 2026)	PHASE3
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)	Merck Sharp & Dohme LLC	NA	RECRUITING (Sep 1, 2026)	PHASE3
Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib	SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany	NA	RECRUITING (Sep 1, 2026)	PHASE1
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)	Merck Sharp & Dohme LLC	NA	RECRUITING (Sep 1, 2026)	PHASE3
Clinical Study of Ensifentrine-Glycopyrrolate (MK-5884A/RPL554) Fixed-dose Combination Dose Ranging in Participants With COPD (MK-5884A-029/RPL554-CO-212)	Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA	NA	COMPLETED (Sep 1, 2026)	PHASE2
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)	Merck Sharp & Dohme LLC	NA	RECRUITING (Sep 1, 2026)	PHASE1, PHASE2
A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)	Merck Sharp & Dohme LLC	NA	RECRUITING (Sep 1, 2026)	PHASE2, PHASE3
A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)	Merck Sharp & Dohme LLC	NA	RECRUITING (Sep 1, 2026)	PHASE3
A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)	Merck Sharp & Dohme LLC	NA	ACTIVE NOT RECRUITING (Sep 1, 2026)	PHASE2
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)	Merck Sharp & Dohme LLC	NA	RECRUITING (Sep 1, 2026)	PHASE3
A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)	Merck Sharp & Dohme LLC	NA	RECRUITING (Sep 1, 2026)	PHASE1
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)	Merck Sharp & Dohme LLC	NA	RECRUITING (Sep 1, 2026)	PHASE3
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)	Merck Sharp & Dohme LLC	NA	RECRUITING (Sep 1, 2026)	PHASE2
A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)	Merck Sharp & Dohme LLC	NA	RECRUITING (Sep 1, 2026)	PHASE2, PHASE3
A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)	Merck Sharp & Dohme LLC	NA	RECRUITING (Sep 1, 2026)	PHASE1, PHASE2
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)	Merck Sharp & Dohme LLC	NA	RECRUITING (Sep 1, 2026)	PHASE3
A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA)	Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany	NA	RECRUITING (Sep 1, 2026)	PHASE3
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)	Merck Sharp & Dohme LLC	NA	RECRUITING (Sep 1, 2026)	PHASE3
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)	Merck Sharp & Dohme LLC	NA	RECRUITING (Sep 1, 2026)	PHASE3
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)	Merck Sharp & Dohme LLC	NA	RECRUITING (Sep 1, 2026)	PHASE3
A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)	Merck Sharp & Dohme LLC	NA	RECRUITING (Sep 1, 2026)	PHASE2
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)	Merck Sharp & Dohme LLC	NA	RECRUITING (Sep 1, 2026)	PHASE2, PHASE3
A Clinical Study of MK-8527 in Healthy Participants (MK-8527-021)	Merck Sharp & Dohme LLC	NA	ACTIVE NOT RECRUITING (Sep 1, 2026)	PHASE1
A Study of Belzutifan in Adolescent Participants With Solid Tumors (MK-9999-01E/LIGHTBEAM-U01)	Merck Sharp & Dohme LLC	NA	NOT YET RECRUITING (Sep 1, 2026)	PHASE2
A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)	Merck Sharp & Dohme LLC	NA	NOT YET RECRUITING (Sep 1, 2026)	PHASE3
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055)	Merck Sharp & Dohme LLC	NA	NOT YET RECRUITING (Sep 1, 2026)	PHASE3
A Clinical Trial to Evaluate MK-4208/TERN-701 in Healthy Adult Participants (MK-4208-001/TERN701-1014)	Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	NA	COMPLETED (Sep 1, 2026)	PHASE1
Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)	Merck Sharp & Dohme LLC	NA	COMPLETED (Aug 1, 2026)	PHASE3
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)	Merck Sharp & Dohme LLC	NA	RECRUITING (Aug 1, 2026)	PHASE1, PHASE2
Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)	Merck Sharp & Dohme LLC	NA	TERMINATED (Aug 1, 2026)	PHASE2
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)	Merck Sharp & Dohme LLC	NA	ACTIVE NOT RECRUITING (Aug 1, 2026)	PHASE3
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension	Merck Sharp & Dohme LLC	NA	COMPLETED (Aug 1, 2026)	PHASE3
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).	Merck Sharp & Dohme LLC	NA	TERMINATED (Aug 1, 2026)	PHASE3
Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)	Merck Sharp & Dohme LLC	NA	TERMINATED (Aug 1, 2026)	PHASE3
A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)	Merck Sharp & Dohme LLC	NA	ACTIVE NOT RECRUITING (Aug 1, 2026)	PHASE1, PHASE2
Mirdametinib + BGB-3245 in Advanced Solid Tumors	SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany	NA	TERMINATED (Aug 1, 2026)	PHASE1, PHASE2
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)	Merck Sharp & Dohme LLC	NA	RECRUITING (Aug 1, 2026)	PHASE2, PHASE3
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study	Merck Sharp & Dohme LLC	NA	ACTIVE NOT RECRUITING (Aug 1, 2026)	PHASE3
A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids	Merck Sharp & Dohme LLC	NA	COMPLETED (Aug 1, 2026)	PHASE3
Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)	Merck Sharp & Dohme LLC	NA	ACTIVE NOT RECRUITING (Aug 1, 2026)	PHASE1
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)	Merck Sharp & Dohme LLC	NA	ACTIVE NOT RECRUITING (Aug 1, 2026)	PHASE3
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)	Merck Sharp & Dohme LLC	NA	ACTIVE NOT RECRUITING (Aug 1, 2026)	PHASE3
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)	Merck Sharp & Dohme LLC	NA	ACTIVE NOT RECRUITING (Aug 1, 2026)	PHASE3
Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)	Merck Sharp & Dohme LLC	NA	ACTIVE NOT RECRUITING (Aug 1, 2026)	PHASE2
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)	Merck Sharp & Dohme LLC	NA	ACTIVE NOT RECRUITING (Aug 1, 2026)	PHASE3
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)	Merck Sharp & Dohme LLC	NA	ACTIVE NOT RECRUITING (Aug 1, 2026)	PHASE3
A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)	Merck Sharp & Dohme LLC	NA	COMPLETED (Aug 1, 2026)	PHASE1
A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis	Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA	NA	RECRUITING (Aug 1, 2026)	PHASE2
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)	Merck Sharp & Dohme LLC	NA	RECRUITING (Aug 1, 2026)	PHASE1, PHASE2
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)	Merck Sharp & Dohme LLC	NA	RECRUITING (Aug 1, 2026)	PHASE2
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)	Merck Sharp & Dohme LLC	NA	RECRUITING (Aug 1, 2026)	PHASE2
Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)	Merck Sharp & Dohme LLC	NA	RECRUITING (Aug 1, 2026)	PHASE2
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)	Merck Sharp & Dohme LLC	NA	RECRUITING (Aug 1, 2026)	PHASE2
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)	Merck Sharp & Dohme LLC	NA	RECRUITING (Aug 1, 2026)	PHASE3
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)	Merck Sharp & Dohme LLC	NA	RECRUITING (Aug 1, 2026)	PHASE2
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)	Merck Sharp & Dohme LLC	NA	RECRUITING (Aug 1, 2026)	PHASE1, PHASE2
A Clinical Study of the Effect of MK-2828 on Rosuvastatin or Furosemide in Healthy People (MK-2828-005)	Merck Sharp & Dohme LLC	NA	COMPLETED (Aug 1, 2026)	PHASE1
A Clinical Trial in Healthy Participants to Learn How Itraconazole Affects MK-2828 Levels and How MK-2828 Affects Midazolam Levels (MK-2828-007)	Merck Sharp & Dohme LLC	NA	COMPLETED (Aug 1, 2026)	PHASE1
A Clinical Trial of MK-4646 With Bictegravir/Emtricitabine/Tenofovir Alafenamide and Dolutegravir in Healthy Adult Participants (MK-4646)	Merck Sharp & Dohme LLC	NA	COMPLETED (Aug 1, 2026)	PHASE1
A Clinical Trial of MK-4082 in Healthy Participants (MK-4082-005)	Merck Sharp & Dohme LLC	NA	RECRUITING (Aug 1, 2026)	PHASE1
A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002)	Merck Sharp & Dohme LLC	NA	NOT YET RECRUITING (Aug 1, 2026)	PHASE2
A Clinical Study of Enlicitide (MK-0616) in Adults With Hyperlipidemia in India (MK-0616-038)	Merck Sharp & Dohme LLC	NA	NOT YET RECRUITING (Aug 1, 2026)	PHASE3
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)	Merck Sharp & Dohme LLC	NA	ACTIVE NOT RECRUITING (Jul 1, 2026)	PHASE1, PHASE2
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)	Merck Sharp & Dohme LLC	NA	ACTIVE NOT RECRUITING (Jul 1, 2026)	PHASE3
Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)	Merck Sharp & Dohme LLC	NA	COMPLETED (Jul 1, 2026)	PHASE3
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)	Merck Sharp & Dohme LLC	NA	ACTIVE NOT RECRUITING (Jul 1, 2026)	PHASE2
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)	Merck Sharp & Dohme LLC	NA	ACTIVE NOT RECRUITING (Jul 1, 2026)	PHASE3
Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)	Merck Sharp & Dohme LLC	NA	COMPLETED (Jul 1, 2026)	PHASE3
Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)	Merck Sharp & Dohme LLC	NA	COMPLETED (Jul 1, 2026)	PHASE3
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)	Merck Sharp & Dohme LLC	NA	COMPLETED (Jul 1, 2026)	PHASE3
Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)	Merck Sharp & Dohme LLC	NA	RECRUITING (Jul 1, 2026)	PHASE2
Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)	Merck Sharp & Dohme LLC	NA	ACTIVE NOT RECRUITING (Jul 1, 2026)	PHASE1, PHASE2
Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)	Merck Sharp & Dohme LLC	NA	ACTIVE NOT RECRUITING (Jul 1, 2026)	PHASE1, PHASE2
Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127)	Merck Sharp & Dohme LLC	NA	RECRUITING (Jul 1, 2026)	PHASE2
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)	Merck Sharp & Dohme LLC	NA	ACTIVE NOT RECRUITING (Jul 1, 2026)	PHASE3
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)	Merck Sharp & Dohme LLC	NA	ACTIVE NOT RECRUITING (Jul 1, 2026)	PHASE3
Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)	Merck Sharp & Dohme LLC	NA	COMPLETED (Jul 1, 2026)	PHASE2
Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)	Merck Sharp & Dohme LLC	NA	COMPLETED (Jul 1, 2026)	PHASE3
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)	Merck Sharp & Dohme LLC	NA	ACTIVE NOT RECRUITING (Jul 1, 2026)	PHASE3
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension	Merck Sharp & Dohme LLC	NA	ACTIVE NOT RECRUITING (Jul 1, 2026)	PHASE3
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)	Merck Sharp & Dohme LLC	NA	RECRUITING (Jul 1, 2026)	PHASE3
A Clinical Trial of MK-8527 and Rifampin in Adult Participants With Latent Tuberculosis Infection (MK-8527-019)	Merck Sharp & Dohme LLC	NA	NOT YET RECRUITING (Jul 1, 2026)	PHASE1
Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)	Merck Sharp & Dohme LLC	NA	COMPLETED (Jun 1, 2026)	PHASE3
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)	Merck Sharp & Dohme LLC	NA	COMPLETED (Jun 1, 2026)	PHASE3
MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas	SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany	NA	ACTIVE NOT RECRUITING (Jun 1, 2026)	PHASE2
Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)	Merck Sharp & Dohme LLC	NA	COMPLETED (Jun 1, 2026)	PHASE2
Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)	Merck Sharp & Dohme LLC	NA	COMPLETED (Jun 1, 2026)	PHASE3
A Drug-Drug Interaction Study of Itraconazole and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-017)	Merck Sharp & Dohme LLC	NA	COMPLETED (Jun 1, 2026)	PHASE1
KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)	Merck Sharp & Dohme LLC	NA	COMPLETED (May 1, 2026)	PHASE2
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)	Merck Sharp & Dohme LLC	NA	ACTIVE NOT RECRUITING (May 1, 2026)	PHASE3
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)	Merck Sharp & Dohme LLC	NA	ACTIVE NOT RECRUITING (May 1, 2026)	PHASE3
Efficacy, Immunogenicity, and Safety Study of V503 (9-valent Human Papillomavirus [9vHPV] Vaccine) in Japanese Males (V503-064)	Merck Sharp & Dohme LLC	NA	COMPLETED (May 1, 2026)	PHASE3
A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018)	Merck Sharp & Dohme LLC	NA	COMPLETED (May 1, 2026)	PHASE1
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)	Merck Sharp & Dohme LLC	NA	COMPLETED (May 1, 2026)	PHASE3
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)	Merck Sharp & Dohme LLC	NA	ACTIVE NOT RECRUITING (May 1, 2026)	PHASE3
Effect of Ensifentrine on Sputum Markers of Inflammation in COPD	Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA	NA	RECRUITING (May 1, 2026)	PHASE2
Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors (MK-1200-002)	Merck Sharp & Dohme LLC	NA	COMPLETED (May 1, 2026)	PHASE1, PHASE2
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)	Merck Sharp & Dohme LLC	NA	RECRUITING (May 1, 2026)	PHASE1, PHASE2
Elpipodect (MK-8189) Multiple Dose Study in Healthy Volunteers and Schizophrenia Participants (MK-8189-003)	Merck Sharp & Dohme LLC	NA	COMPLETED (Apr 1, 2026)	PHASE1
An Active-Controlled Early Phase Study of Elpipodect (MK-8189) in Adults With Schizophrenia (MK-8189-005)	Merck Sharp & Dohme LLC	NA	COMPLETED (Apr 1, 2026)	PHASE2
A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)	Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	NA	ACTIVE NOT RECRUITING (Apr 1, 2026)	PHASE2
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)	Merck Sharp & Dohme LLC	NA	COMPLETED (Apr 1, 2026)	PHASE3
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)	Merck Sharp & Dohme LLC	NA	ACTIVE NOT RECRUITING (Apr 1, 2026)	PHASE3
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)	Merck Sharp & Dohme LLC	NA	ACTIVE NOT RECRUITING (Apr 1, 2026)	PHASE3
Efficacy and Safety of Elpipodect (MK-8189) in Participants With an Acute Episode of Schizophrenia (MK-8189-008)	Merck Sharp & Dohme LLC	NA	COMPLETED (Apr 1, 2026)	PHASE2
Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024)	Merck Sharp & Dohme LLC	NA	TERMINATED (Apr 1, 2026)	PHASE3
Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)	Merck Sharp & Dohme LLC	NA	COMPLETED (Apr 1, 2026)	PHASE3
Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)-China Extension Study	Merck Sharp & Dohme LLC	NA	COMPLETED (Apr 1, 2026)	PHASE3
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)	Merck Sharp & Dohme LLC	NA	ACTIVE NOT RECRUITING (Apr 1, 2026)	PHASE3
A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005)	Merck Sharp & Dohme LLC	NA	COMPLETED (Apr 1, 2026)	PHASE1
To Determine the Effect of CYP Induction Following Administration of Nirogacestat in Healthy Adult Male Participants	SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany	NA	COMPLETED (Apr 1, 2026)	PHASE1
Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)	Merck Sharp & Dohme LLC	NA	COMPLETED (Mar 1, 2026)	PHASE3
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).	Merck Sharp & Dohme LLC	NA	ACTIVE NOT RECRUITING (Mar 1, 2026)	PHASE3
A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001)	Merck Sharp & Dohme LLC	NA	COMPLETED (Mar 1, 2026)	PHASE1
A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)	Merck Sharp & Dohme LLC	NA	COMPLETED (Mar 1, 2026)	PHASE3
An Ethno-bridging Study of Pergoveris in Healthy Premenopausal Participants of Japanese or Caucasian Origin	Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany	NA	COMPLETED (Mar 1, 2026)	PHASE1
To Assess the Enzyme Inducing Effects of Carbamazepine on the PK of Mirdametinib in Healthy Participants	SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany	NA	COMPLETED (Mar 1, 2026)	PHASE1
A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008)	Merck Sharp & Dohme LLC	NA	COMPLETED (Jan, 2019)	PHASE2
A Study of the Pharmacokinetics and Pharmacodynamics of Vibegron (MK-4618) in Women With Overactive Bladder (MK-4618-004)	Merck Sharp & Dohme LLC	NA	TERMINATED (Dec, 2018)	PHASE1
A Single Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Participants With Renal Insufficiency (MK-4618-014)	Merck Sharp & Dohme LLC	NA	COMPLETED (Dec, 2018)	PHASE1
A Single-Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Adults With Hepatic Insufficiency (MK-4618-013)	Merck Sharp & Dohme LLC	NA	COMPLETED (Dec, 2018)	PHASE1

Merck Drug List

Given below is the complete list of Merck's drugs and the patents protecting them.

1. Belsomra

Belsomra is protected by 4 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US10098892	Solid dosage formulations of an orexin receptor antagonist	29 May, 2033 (6 years from now)	Active
US11980623	Solid dosage formulations of an orexin receptor antagonist	29 May, 2033 (6 years from now)	Active
US12599610	Solid Dosage Formulations Of An Orexin Receptor Antagonist	29 May, 2033 (6 years from now)	Active
US7951797	Substituted diazepan orexin receptor antagonists	20 Nov, 2029 (3 years from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Belsomra's drug page

2. Bridion

Bridion is protected by 5 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
USRE44733 (Pediatric)	6-mercapto-cyclodextrin derivatives:reversal agents for drug-induced neuromuscular block	27 Jul, 2026 (2 months ago)	Expired
USRE44733	6-mercapto-cyclodextrin derivatives:reversal agents for drug-induced neuromuscular block	27 Jan, 2026 (8 months ago)	Expired
US6949527	6-Mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block	27 Jan, 2021 (5 years ago)	Expired
US7265009	HDP-CVD methodology for forming PMD layer	07 Aug, 2020 (6 years ago)	Expired
US7265099	Use of chemical chelators as reversal agents for drug-induced neuromuscular block	07 Aug, 2020 (6 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Bridion's drug page

3. Cancidas

Cancidas is protected by 10 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US5952300 (Pediatric)	Antifungal compositions	28 Sep, 2017 (9 years ago)	Expired
US6136783 (Pediatric)	Antifungal compositions	28 Sep, 2017 (9 years ago)	Expired
US5952300	Antifungal compositions	28 Mar, 2017 (9 years ago)	Expired
US6136783	Antifungal compositions	28 Mar, 2017 (9 years ago)	Expired
US5514650 (Pediatric)	Aza cyclohexapeptide compounds	26 Jul, 2015 (11 years ago)	Expired
US5514650	Aza cyclohexapeptide compounds	26 Jan, 2015 (11 years ago)	Expired
US5378804 (Pediatric)	Aza cyclohexapeptide compounds	16 Sep, 2013 (13 years ago)	Expired
US5792746 (Pediatric)	Aza cyclohexapeptide compounds	16 Sep, 2013 (13 years ago)	Expired
US5378804	Aza cyclohexapeptide compounds	16 Mar, 2013 (13 years ago)	Expired
US5792746	Aza cyclohexapeptide compounds	16 Mar, 2013 (13 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cancidas's drug page

4. Crixivan

Crixivan is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US6689761	Combination therapy for HIV infection	10 Feb, 2021 (5 years ago)	Expired
US6645961	Dry granulation formulation for an HIV protease inhibitor	04 Mar, 2018 (8 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Crixivan's drug page

5. Delstrigo

Delstrigo is protected by 3 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US10603282	Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine	29 Nov, 2036 (10 years from now)	Active
US10842751	Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine	29 Nov, 2036 (10 years from now)	Active
US8486975	Non-nucleoside reverse transcriptase inhibitors	30 Aug, 2032 (5 years from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Delstrigo's drug page

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue

Explore the top-performing drugs that dominate the pharmaceutical industry

View List

NCE-1 Patent Expiry in the Next 1 Year

Identify opportunities as new chemical entity (NCE-1) patents approach expiry

View List

Recently Granted Patents in EP

Find the opportunity to file Oppositions

View List

6. Dutrebis

Dutrebis is protected by 9 patents, out of which 7 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US7754731 (Pediatric)	Potassium salt of an HIV integrase inhibitor	11 Sep, 2029 (2 years from now)	Active
US7754731	Potassium salt of an HIV integrase inhibitor	11 Mar, 2029 (2 years from now)	Active
US7169780 (Pediatric)	N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase	03 Apr, 2024 (2 years ago)	Expired
US7169780	N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase	03 Oct, 2023 (3 years ago)	Expired
US7820660	N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase	25 Apr, 2023 (3 years ago)	Expired
US7217713 (Pediatric)	N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase	21 Apr, 2023 (3 years ago)	Expired
US7435734 (Pediatric)	N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase	21 Apr, 2023 (3 years ago)	Expired
US7217713	N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase	21 Oct, 2022 (3 years ago)	Expired
US7435734	N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase	21 Oct, 2022 (3 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Dutrebis's drug page

7. Emend

Emend is protected by 9 patents, out of which 8 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8258132	Pharmaceutical composition of a tachykinin receptor antagonist	26 Sep, 2027 (11 months from now)	Active
US5691336 (Pediatric)	Morpholine compounds are prodrugs useful as tachykinin receptor antagonists	04 Sep, 2019 (7 years ago)	Expired
US5691336	Morpholine compounds are prodrugs useful as tachykinin receptor antagonists	04 Mar, 2019 (7 years ago)	Expired
US6096742	Polymorphic form of a tachykinin receptor antagonist	01 Jul, 2018 (8 years ago)	Expired
US5719147	Morpholine and thiomorpholine tachykinin receptor antagonists	17 Apr, 2015 (11 years ago)	Expired
US5716942	Treatment of migraine with morpholine tachykinin receptor antagonists	10 Feb, 2015 (11 years ago)	Expired
US5512570	Treatment of emesis with morpholine tachykinin receptor antagonists	04 Mar, 2014 (12 years ago)	Expired
US5538982	Medical use for tachykinin antagonists	23 Jul, 2013 (13 years ago)	Expired
US7214692	Medical use for tachykinin antagonists	18 Sep, 2012 (14 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Emend's drug page

8. Fosamax

Fosamax is protected by 8 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US5994329 (Pediatric)	Method for inhibiting bone resorption	17 Jan, 2019 (7 years ago)	Expired
US6015801 (Pediatric)	Method for inhibiting bone resorption	17 Jan, 2019 (7 years ago)	Expired
US6225294 (Pediatric)	Method for inhibiting bone resorption	17 Jan, 2019 (7 years ago)	Expired
US5994329	Method for inhibiting bone resorption	17 Jul, 2018 (8 years ago)	Expired
US6015801	Method for inhibiting bone resorption	17 Jul, 2018 (8 years ago)	Expired
US6225294	Method for inhibiting bone resorption	17 Jul, 2018 (8 years ago)	Expired
US5462932 (Pediatric)	Oral liquid alendronate formulations	17 Nov, 2014 (11 years ago)	Expired
US5462932	Oral liquid alendronate formulations	17 May, 2014 (12 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Fosamax's drug page

9. Idvynso

Idvynso is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8486975	Non-nucleoside reverse transcriptase inhibitors	30 Aug, 2032 (5 years from now)	Active
US7339053	4'-C-Substituted-2-Haloadenosine Derivative	31 May, 2027 (7 months from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Idvynso's drug page

10. Integrilin

Integrilin is protected by 5 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US5807825	Platelet aggregation inhibitors	15 Sep, 2015 (11 years ago)	Expired
US5968902	Platelet aggregation inhibitors	02 Jun, 2015 (11 years ago)	Expired
US5747447	Stable polypeptide composition	05 May, 2015 (11 years ago)	Expired
US5686570	Platelet aggregation inhibitors	11 Nov, 2014 (11 years ago)	Expired
US5756451	Platelet aggregation inhibitors	11 Nov, 2014 (11 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Integrilin's drug page

11. Invanz

Invanz is protected by 8 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US5952323 (Pediatric)	Carbapenem antibiotic	15 Nov, 2017 (8 years ago)	Expired
US5952323	Carbapenem antibiotic	15 May, 2017 (9 years ago)	Expired
US5478820 (Pediatric)	Antibiotic compounds	21 May, 2016 (10 years ago)	Expired
US5478820	Antibiotic compounds	21 Nov, 2015 (10 years ago)	Expired
US5652233 (Pediatric)	Antibiotic compounds	02 Aug, 2013 (13 years ago)	Expired
US7342005 (Pediatric)	Antibiotic compounds	02 Aug, 2013 (13 years ago)	Expired
US5652233	Antibiotic compounds	02 Feb, 2013 (13 years ago)	Expired
US7342005	Antibiotic compounds	02 Feb, 2013 (13 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Invanz's drug page

12. Isentress

Isentress is protected by 10 patents, out of which 6 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8771733	Pharmaceutical composition containing an anti-nucleating agent	02 Jun, 2030 (3 years from now)	Active
US7754731 (Pediatric)	Potassium salt of an HIV integrase inhibitor	11 Sep, 2029 (2 years from now)	Active
US7754731	Potassium salt of an HIV integrase inhibitor	11 Mar, 2029 (2 years from now)	Active
US8852632	Pharmaceutical formulation containing a release rate controlling composition	28 Jan, 2028 (1 year, 3 months from now)	Active
US7169780 (Pediatric)	N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase	03 Apr, 2024 (2 years ago)	Expired
US7169780	N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase	03 Oct, 2023 (3 years ago)	Expired
US7217713 (Pediatric)	N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase	21 Apr, 2023 (3 years ago)	Expired
US7435734 (Pediatric)	N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase	21 Apr, 2023 (3 years ago)	Expired
US7217713	N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase	21 Oct, 2022 (3 years ago)	Expired
US7435734	N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase	21 Oct, 2022 (3 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Isentress's drug page

13. Isentress Hd

Isentress Hd is protected by 12 patents, out of which 6 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US10772888	Solid pharmaceutical compositions containing an integrase inhibitor	30 Mar, 2032 (5 years from now)	Active
US9649311 (Pediatric)	Solid pharmaceutical compositions containing an integrase inhibitor	21 Apr, 2031 (4 years from now)	Active
US9649311	Solid pharmaceutical compositions containing an integrase inhibitor	21 Oct, 2030 (4 years from now)	Active
US8771733	Pharmaceutical composition containing an anti-nucleating agent	02 Jun, 2030 (3 years from now)	Active
US7754731 (Pediatric)	Potassium salt of an HIV integrase inhibitor	11 Sep, 2029 (2 years from now)	Active
US7754731	Potassium salt of an HIV integrase inhibitor	11 Mar, 2029 (2 years from now)	Active
US7169780 (Pediatric)	N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase	03 Apr, 2024 (2 years ago)	Expired
US7169780	N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase	03 Oct, 2023 (3 years ago)	Expired
US7217713 (Pediatric)	N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase	21 Apr, 2023 (3 years ago)	Expired
US7435734 (Pediatric)	N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase	21 Apr, 2023 (3 years ago)	Expired
US7217713	N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase	21 Oct, 2022 (3 years ago)	Expired
US7435734	N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase	21 Oct, 2022 (3 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Isentress Hd's drug page

14. Janumet

Janumet is protected by 12 patents, out of which 8 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8414921 (Pediatric)	Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin	21 Jan, 2029 (2 years from now)	Active
US8414921	Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin	21 Jul, 2028 (1 year, 9 months from now)	Active
US7326708 (Pediatric)	Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor	24 May, 2027 (7 months from now)	Active
US7326708	Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor	24 Nov, 2026 (a month from now)	Active
US6699871 (Pediatric)	Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes	26 Jan, 2023 (3 years ago)	Expired
US7125873 (Pediatric)	Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes	26 Jan, 2023 (3 years ago)	Expired
US6699871	Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes	26 Jul, 2022 (4 years ago)	Expired
US7125873	Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes	26 Jul, 2022 (4 years ago)	Expired
US6890898	Method of regulating glucose metabolism, and reagents related thereto	02 Feb, 2019 (7 years ago)	Expired
US7078381	Method of regulating glucose metabolism, and reagents related thereto	02 Feb, 2019 (7 years ago)	Expired
US7459428	Method of regulating glucose metabolism, and reagents related thereto	02 Feb, 2019 (7 years ago)	Expired
US6303661	Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals	24 Apr, 2017 (9 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Janumet's drug page

15. Janumet Xr

Janumet Xr is protected by 12 patents, out of which 10 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US7326708 (Pediatric)	Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor	24 May, 2027 (7 months from now)	Active
US7326708	Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor	24 Nov, 2026 (a month from now)	Active
US6699871 (Pediatric)	Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes	26 Jan, 2023 (3 years ago)	Expired
US7125873 (Pediatric)	Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes	26 Jan, 2023 (3 years ago)	Expired
US6699871	Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes	26 Jul, 2022 (4 years ago)	Expired
US7125873	Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes	26 Jul, 2022 (4 years ago)	Expired
US6890898	Method of regulating glucose metabolism, and reagents related thereto	02 Feb, 2019 (7 years ago)	Expired
US7078381	Method of regulating glucose metabolism, and reagents related thereto	02 Feb, 2019 (7 years ago)	Expired
US7459428	Method of regulating glucose metabolism, and reagents related thereto	02 Feb, 2019 (7 years ago)	Expired
US6303661	Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals	24 Apr, 2017 (9 years ago)	Expired
US6340475	Extending the duration of drug release within the stomach during the fed mode	19 Sep, 2016 (10 years ago)	Expired
US6635280	Extending the duration of drug release within the stomach during the fed mode	19 Sep, 2016 (10 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Janumet Xr's drug page

16. Januvia

Januvia is protected by 10 patents, out of which 8 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US7326708 (Pediatric)	Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor	24 May, 2027 (7 months from now)	Active
US7326708	Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor	24 Nov, 2026 (a month from now)	Active
US6699871 (Pediatric)	Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes	26 Jan, 2023 (3 years ago)	Expired
US7125873 (Pediatric)	Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes	26 Jan, 2023 (3 years ago)	Expired
US6699871	Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes	26 Jul, 2022 (4 years ago)	Expired
US7125873	Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes	26 Jul, 2022 (4 years ago)	Expired
US6890898	Method of regulating glucose metabolism, and reagents related thereto	02 Feb, 2019 (7 years ago)	Expired
US7078381	Method of regulating glucose metabolism, and reagents related thereto	02 Feb, 2019 (7 years ago)	Expired
US7459428	Method of regulating glucose metabolism, and reagents related thereto	02 Feb, 2019 (7 years ago)	Expired
US6303661	Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals	24 Apr, 2017 (9 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Januvia's drug page

17. Juvisync

Juvisync is protected by 11 patents, out of which 10 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US7326708 (Pediatric)	Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor	11 Oct, 2026 (5 days from now)	Active
US7326708	Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor	11 Apr, 2026 (5 months ago)	Expired
US6699871 (Pediatric)	Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes	26 Jan, 2023 (3 years ago)	Expired
US7125873 (Pediatric)	Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes	26 Jan, 2023 (3 years ago)	Expired
US6699871	Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes	26 Jul, 2022 (4 years ago)	Expired
US7125873	Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes	26 Jul, 2022 (4 years ago)	Expired
US8168637	Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment of diabetes	26 Jun, 2022 (4 years ago)	Expired
US6890898	Method of regulating glucose metabolism, and reagents related thereto	02 Feb, 2019 (7 years ago)	Expired
US7078381	Method of regulating glucose metabolism, and reagents related thereto	02 Feb, 2019 (7 years ago)	Expired
US7459428	Method of regulating glucose metabolism, and reagents related thereto	02 Feb, 2019 (7 years ago)	Expired
US6303661	Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals	24 Apr, 2017 (9 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Juvisync's drug page

18. Lipfendra

Lipfendra is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US11427616	Pcsk9 Antagonist Compounds	04 Feb, 2040 (13 years from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lipfendra's drug page

19. Noxafil

Noxafil is protected by 8 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US9493582	Alkylated cyclodextrin compositions and processes for preparing and using the same	27 Feb, 2033 (6 years from now)	Active
US9023790	Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin	04 Jul, 2031 (4 years from now)	Active
US9358297	Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin	24 Jun, 2031 (4 years from now)	Active
US10117951	Sulfoalkyl ether cyclodextrin compositions	13 Mar, 2029 (2 years from now)	Active
US8410077	Sulfoalkyl ether cyclodextrin compositions	13 Mar, 2029 (2 years from now)	Active
US9750822	Sulfoalkyl ether cyclodextrin compositions	13 Mar, 2029 (2 years from now)	Active
US5661151	Tetrahydrofuran antifungals	19 Jul, 2019 (7 years ago)	Expired
US5703079	Tetrahydrofuran antifungals	26 Aug, 2014 (12 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Noxafil's drug page

20. Ohtuvayre

Ohtuvayre is protected by 5 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US12251384	Particulate composition	25 Jun, 2044 (17 years from now)	Active
US12409180	Formulation Production Process	20 Feb, 2043 (16 years from now)	Active
US10945950	Liquid inhalation formulation comprising RPL554	15 Sep, 2035 (8 years from now)	Active
US9956171	Liquid inhalation formulation comprising RPL554	15 Sep, 2035 (8 years from now)	Active
US9062047	Crystalline form of pyrimido[6,1-A] isoquinolin-4-one compound	21 Aug, 2031 (4 years from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ohtuvayre's drug page

21. Pifeltro

Pifeltro is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8486975	Non-nucleoside reverse transcriptase inhibitors	30 Aug, 2032 (5 years from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Pifeltro's drug page

22. Prevymis

Prevymis is protected by 4 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US10603384	Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative	28 Feb, 2033 (6 years from now)	Active
USRE46791	Substituted dihydroquinazolines	18 Jan, 2029 (2 years from now)	Active
US7196086	Substituted dihydroquinazolines	22 May, 2024 (2 years ago)	Expired
US8513255	Substituted dihydroquinazolines	22 May, 2024 (2 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Prevymis's drug page

23. Rebetol

Rebetol is protected by 10 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US6172046 (Pediatric)	Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection	21 Mar, 2018 (8 years ago)	Expired
US6472373 (Pediatric)	Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection	21 Mar, 2018 (8 years ago)	Expired
US6172046	Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection	21 Sep, 2017 (9 years ago)	Expired
US6472373	Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection	21 Sep, 2017 (9 years ago)	Expired
US6177074 (Pediatric)	Polyethylene glycol modified interferon therapy	01 May, 2017 (9 years ago)	Expired
US6461605 (Pediatric)	Continuous low-dose cytokine infusion therapy	01 May, 2017 (9 years ago)	Expired
US6524570 (Pediatric)	Polyethylene glycol modified interferon therapy	01 May, 2017 (9 years ago)	Expired
US6177074	Polyethylene glycol modified interferon therapy	01 Nov, 2016 (9 years ago)	Expired
US6461605	Continuous low-dose cytokine infusion therapy	01 Nov, 2016 (9 years ago)	Expired
US6524570	Polyethylene glycol modified interferon therapy	01 Nov, 2016 (9 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rebetol's drug page

24. Recarbrio

Recarbrio is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8487093	β-lactamase inhibitors	21 Mar, 2033 (6 years from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Recarbrio's drug page

25. Segluromet

Segluromet is protected by 3 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8080580	Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives	19 Dec, 2031 (5 years from now)	Active
US9308204	Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives	21 Oct, 2030 (4 years from now)	Active
US9439902	Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives	21 Oct, 2030 (4 years from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Segluromet's drug page

26. Steglatro

Steglatro is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8080580	Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives	19 Dec, 2031 (5 years from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Steglatro's drug page

27. Steglujan

Steglujan is protected by 10 patents, out of which 5 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8080580	Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives	19 Dec, 2031 (5 years from now)	Active
US9308204	Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives	21 Oct, 2030 (4 years from now)	Active
US9439901	Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives	21 Oct, 2030 (4 years from now)	Active
US7326708 (Pediatric)	Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor	24 May, 2027 (7 months from now)	Active
US7326708	Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor	24 Nov, 2026 (a month from now)	Active
US6699871 (Pediatric)	Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes	26 Jan, 2023 (3 years ago)	Expired
US6699871	Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes	26 Jul, 2022 (4 years ago)	Expired
US6890898	Method of regulating glucose metabolism, and reagents related thereto	02 Feb, 2019 (7 years ago)	Expired
US7078381	Method of regulating glucose metabolism, and reagents related thereto	02 Feb, 2019 (7 years ago)	Expired
US7459428	Method of regulating glucose metabolism, and reagents related thereto	02 Feb, 2019 (7 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Steglujan's drug page

28. Temodar

Temodar is protected by 5 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US6987108	Pharmaceutical formulations of antineoplastic agents and processes of making and using the same	08 Sep, 2023 (3 years ago)	Expired
US7786118	Pharmaceutical formulations of antineoplastic agents	21 Feb, 2023 (3 years ago)	Expired
US8623868	Processes of making and using pharmaceutical formulations of antineoplastic agents	21 Feb, 2023 (3 years ago)	Expired
US5260291 (Pediatric)	Tetrazine derivatives	11 Feb, 2014 (12 years ago)	Expired
US5260291	Tetrazine derivatives	11 Aug, 2013 (13 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Temodar's drug page

29. Verquvo

Verquvo is protected by 6 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US9604948	Process for preparing substituted 5-fluoro-1H-pyrazolopyridines	26 Nov, 2032 (6 years from now)	Active
US10736896	Substituted 5-fluoro-1H-pyrazolopyridines and their use	19 May, 2031 (4 years from now)	Active
US11439642	Substituted 5-fluoro-1H-pyrazolopyridines and their use	19 May, 2031 (4 years from now)	Active
US8420656	Substituted 5-fluoro-1H-pyrazolopyridines and their use	19 May, 2031 (4 years from now)	Active
US8921377	Substituted 5-fluoro-1H-pyrazolopyridines and their use	19 May, 2031 (4 years from now)	Active
US9993476	Substituted 5-flouro-1H-pyrazolopyridines and their use	19 May, 2031 (4 years from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Verquvo's drug page

30. Victrelis

Victrelis is protected by 3 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US7772178	Pharmaceutical formulations and methods of treatment using the same	11 Nov, 2027 (1 year, 1 month from now)	Active
US8119602	Administration of HCV protease inhibitors in combination with food to improve bioavailability	17 Mar, 2027 (5 months from now)	Active
USRE43298	Peptides as NS3-serine protease inhibitors of hepatitis C virus	22 Dec, 2024 (1 year, 9 months ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Victrelis's drug page

31. Vioxx

Vioxx is protected by 8 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US6063811 (Pediatric)	Compositions for a once day treatment of cyclooxygenase-2 mediated diseases	06 Nov, 2017 (8 years ago)	Expired
US6063811	Compositions for a once day treatment of cyclooxygenase-2 mediated diseases	06 May, 2017 (9 years ago)	Expired
US5691374 (Pediatric)	Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors	18 Nov, 2015 (10 years ago)	Expired
US5691374	Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors	18 May, 2015 (11 years ago)	Expired
US5474995 (Pediatric)	Phenyl heterocycles as cox-2 inhibitors	24 Dec, 2013 (12 years ago)	Expired
US6239173 (Pediatric)	3-phenyl-4-(4(methylsulfonyl)phenyl)-2-(5H)-furanone as a cox-2 inhibitor	24 Dec, 2013 (12 years ago)	Expired
US5474995	Phenyl heterocycles as cox-2 inhibitors	24 Jun, 2013 (13 years ago)	Expired
US6239173	3-phenyl-4-(4(methylsulfonyl)phenyl)-2-(5H)-furanone as a cox-2 inhibitor	24 Jun, 2013 (13 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vioxx's drug page

32. Welireg

Welireg is protected by 5 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US12358870	Solid Dispersions And Pharmaceutical Compositions Comprising A Substituted Indane And Methods For The Preparation And Use Thereof	30 Jun, 2042 (15 years from now)	Active
US10335388	Combination Therapy Of A Hif-2-Alpha Inhibitor And An Immunotherapeutic Agent And Uses Thereof	14 Apr, 2036 (9 years from now)	Active
US9908845	Aryl ethers and uses thereof	05 Sep, 2034 (7 years from now)	Active
US9969689	Aryl ethers and uses thereof	05 Sep, 2034 (7 years from now)	Active
USRE49948	Aryl ethers and uses thereof	05 Sep, 2034 (7 years from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Welireg's drug page

33. Zepatier

Zepatier is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8871759	Inhibitors of hepatitis C virus replication	04 May, 2031 (4 years from now)	Active
US7973040	Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors	24 Jul, 2029 (2 years from now)	Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zepatier's drug page

34. Zolinza

Zolinza is protected by 10 patents, out of which 8 have expired. Check out its patent list below.

Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Status
US8450372	Formulations of suberoylanilide hydroxamic acid and methods for producing same	18 Mar, 2028 (1 year, 5 months from now)	Active
US7456219	Polymorphs of suberoylanilide hydroxamic acid	11 Mar, 2027 (5 months from now)	Active
US8093295	Formulations of suberoylanilide hydroxamic acid and methods for producing the same	16 May, 2026 (4 months ago)	Expired
US7399787	Methods of treating cancer with HDAC inhibitors	09 Feb, 2025 (1 year, 7 months ago)	Expired
US7851509	Polymorphs of suberoylanilide hydroxamic acid	21 Feb, 2024 (2 years ago)	Expired
US7652069	Polymorphs of suberoylanilide hydroxamic acid	04 Mar, 2023 (3 years ago)	Expired
US7732490	Methods of treating cancer	04 Mar, 2023 (3 years ago)	Expired
US8067472	Methods of treating Hodgkin's and non-Hodgkin's lymphoma	04 Mar, 2023 (3 years ago)	Expired
US8101663	Polymorphs of suberoylanilide hydroxamic acid	04 Mar, 2023 (3 years ago)	Expired
USRE38506	Potent inducers of terminal differentiation and methods of use thereof	29 Nov, 2013 (12 years ago)	Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zolinza's drug page

Pharsight

Pharsight

Latest Legal Activities on Merck's Drug Patents

Merck's Drug Patent Litigations

Merck Drug Patents' Oppositions Filed in EPO

Merck's Family Patents

Clinical Trials

Recent Clinical Trials by Merck:

Merck Drug List

Explore Our Curated Drug Screens

Merck News

Related content

Have Questions?